BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia

European Neuropsychopharmacology

Volumn 19, Issue 1, 2009, Pages 1-13

  Geffen, Yona ^a   Nudelman, Abraham ^b   Gil Ad, Irit ^c   Rephaeli, Ada ^c   Huang, Mei ^d   Savitsky, Kinneret ^a   Klapper, Leah ^a   Winkler, Ilan ^a   Meltzer, Herbert Y ^d   Weizman, Abraham ^c  

^a BIOLINERX LTD   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Dopamine; GABA; Perphenazine; Schizophrenia; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID 2 [4 [3 (2 CHLOROPHENOTHIAZIN 10 YL)PROPYL]PIPERAZIN 1 YL]ETHYL ESTER; 4 AMINOBUTYRIC ACID 2 [4 [3 (2 CHLOROPHENOTHIAZIN 10 YL)PROPYL]PIPERAZIN 1 YL]ETHYL ESTER C 14; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; AMPHETAMINE; BL 1020; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; MUSCARINIC M1 RECEPTOR; MUSCARINIC M3 RECEPTOR; NEUROLEPTIC AGENT; PERPHENAZINE; PROLACTIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 5A RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RECEPTOR BINDING; GABAERGIC SYSTEM; HIPPOCAMPUS; HYPERACTIVITY; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA; SEDATION; SINGLE DRUG DOSE;

ACETYLCHOLINE; AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BRAIN; CATALEPSY; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; MALE; MICRODIALYSIS; MOTOR ACTIVITY; PERPHENAZINE; PREFRONTAL CORTEX; PROLACTIN; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SCHIZOPHRENIA; TISSUE DISTRIBUTION;

EID: 57149109317     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.07.002     Document Type: Article

References (52)

1. Balant-Gorgio A.E., and Balant L. Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin. Pharmacokinet. 13 (1987) 65-90
2. Benes F.M., and Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25 (2001) 1-27
3. Blum B.P., and Mann J.J. The GABAergic system in schizophrenia. Int. J. Neuropsychopharmacol. 5 (2002) 159-179
4. Boissier J.R., and Simon P. Action of caffeine on the spontaneous motility of the mouse. Arch. Int. Pharmacodyn. Ther. 158 (1965) 212-221
5. Carpenter Jr. W.T., Buchanan R.W., Kirkpatrick B., and Breier A.F. Diazepam treatment of early signs of exacerbation in schizophrenia. Am. J. Psychiatry 156 (1999) 299-303
6. Caruncho H.J., Dopeso-Reyes I.G., Loza M.I., and Rodriguez M.A. A GABA, reelin, and the neurodevelopmental hypothesis of schizophrenia. Crit. Rev. Neurobiol. 16 (2004) 25-32
7. Casey D.E. Pathophysiology of antipsychotic drug-induced movement disorders. J. Clin. Psychiatry 65 Suppl. 9 (2004) 25-28
8. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant, (K1) and the concentration of inhibitor which causes 50 per cent inhibition, (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
9. Chermat R., and Simon P. Appréciation de la catalepsie chez le rat. J. Pharmcol. (Paris) 6 (1975) 493-496
10. Costa E., Davis J.M., Dong E., Grayson D.R., Guidotti A., Tremolizzo L., and Veldic M. A GABAergic cortical deficit dominates schizophrenia pathophysiology. Crit. Rev. Neurobiol. 16 (2004) 1-23
11. Coyle J.T. The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochem. Pharmacol. 68 (2004) 1507-1514
12. Davis J.M. The choice of drugs for schizophrenia. N. Engl. J. Med. 354 (2006) 518-520
13. Fatemi S.H., Stary J.M., Earle J.A., Raghi-Niknam M., and Eagan E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr. Res. 72 (2005) 109-122
14. Freedman R. Schizophrenia. N. Engl. J. Med. 349 (2003) 1738-1749
15. Freedman R. The choice of antipsychotic drugs for schizophrenia. N. Engl. J. Med. 353 (2005) 1286-1288
16. Glenthoj B.Y., and Hemmingsen R. Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 21 (1997) 23-46
17. Grayson D.R., Chen Y., Costa E., Dong E., Guidotti A., Kundakovic M., and Sharma R.P. The human reelin gene: transcription factors (+), repressors (-) and the methylation switch (+/-) in schizophrenia. Pharmacol. Ther. 111 (2006) 272-286
18. Guidotti A., Auta J., Davis J.M., Dong E., Grayson D.R., Veldic M., Zhang X., and Costa E. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) 180 (2005) 191-205
19. Gupta S., Jain S., Brahmachari S.K., and Kukreti R. Pharmacogenomics: a path to predictive medicine for schizophrenia. Pharmacogenomics 7,3 (2006) 1-47
20. Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64 (2004) 2291-2314
21. Halbreich U., and Kahn L.S. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J. Psychiatr. Pract. 9 (2003) 344-353
22. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10 (2005) 40-68
23. Hosak L., and Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur. Psychiatry 17 (2002) 371-378
24. Howard A., Tamas G., and Soltesz I. Lighting the chandelier: new vistas for axo-axonic cells. Trends Neurosci. 28 (2005) 310-316
25. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., and Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76 (2001) 1521-1531
26. Ichikawa J., Chung Y.C., Dai J., and Meltzer H.Y. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release. Brain Res. 1052 (2005) 56-62
27. Irwin S. Considerations for the pre-clinical evaluation of new psychiatric drugs: a case study with phenothiazine-like tranquilizers. Psychopharmacologia 9 (1966) 259-287
28. Keverne E.B. GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Brain Res. Bull. 48 (1999) 467-473
29. Kuriyama K., and Sze P.Y. Blood-brain barrier to H3-gamma-aminobutyric acid in normal and amino oxyacetic acid-treated animals. Neuropharmacology 10 (1971) 103-108
30. Laruelle M., and bi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 13 (1999) 358-371
31. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev., Neurosci. 6 (2005) 312-324
32. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
33. Mamo D., Graff A., Mizrahi R., Shammi C.M., Romeyer F., and Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J. Psychiatry 164, (2007) 1411-1417
34. Maneuf Y.P., Gonzalez M.I., Sutton K.S., Chung F.Z., Pinnock R.D., and Lee K. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell. Mol. Life Sci. 60 (2003) 742-750
35. Marek G., and Merchant K. Developing therapeutics for schizophrenia and other psychotic disorders. NeuroRx. 2 (2005) 579-589
36. Marsden C.A. Dopamine: the rewarding years. Br. J. Pharmacol. 147 Suppl 1 (2006) S136-S144
37. Mueser K.T., and McGurk S.R. Schizophrenia. Lancet 363 (2004) 2063-2072
38. Nudelman A., Gil-Ad I., Shpaisman N., Terasenko I., Ron H., Savitsky K., Geffen Y., Weizman A., and Rephaeli A. BL-1020 a mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. J Med. Chem. 51 (2008) 2858-2862
39. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. Fourth Edition (1998), Academic Press, Spiral Bound, New York
40. Podhorna J., and Didriksen M. The heterozygous reeler mouse: behavioural phenotype. Behav. Brain Res. 153 (2004) 43-54
41. Roth B.L., Sheffler D.J., and Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev., Drug Discov. 3 (2004) 353-359
42. Rudolph U., and Möhler H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr. Opin. Pharmacol. 6 (2006) 18-23
43. Shukla V.K., Garg S.K., Mathur V.S., and Kulkarni S.K. GABAergic, dopaminergic and cholinergic interactions in perphenazine-induced catatonia in rats. Arch. Int. Pharmacodyn. Ther. 278 (1985) 236-248
44. Siuciak J.A., Chapin D.S., McCarthy S.A., Guanowsky V., Brown J.C., Phoebe Marala R., Patterson T., Seymour P.A., Swick A., and Iredale P.A. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52 (2007) 279-290
45. Soares K., Rathbone J., and Deeks J. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. 4 (2004) CD000203
46. Stroup T.S., Alves W.M., Hamer R.M., and Lieberman J.A. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat. Rev. Drug Discov. 5 (2006) 133-146
47. Wassef A., Baker J., and Kochan L.D. GABA and schizophrenia: a review of basic science and clinical studies. J. Clin. Psychopharmacol. 23 (2003) 601-640
48. Wong C.G., Bottiglieri T., and Snead III O.C. GABA, gamma-hydroxybutyric acid, and neurological disease. Ann. Neurol. 54 Suppl. 6 (2003) S3-S12
49. Woo N.H., and Lu B. Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders. Neuroscientist 12 (2006) 43-56
50. Yang C.R., Seamans J.K., and Gorelova N. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 21 (1999) 161-194
51. A receptors to a dopamine hyperfunction. Proc. Natl. Acad. Sci. U. S. A 102 (2005) 17154-17159
52. Zink M., Schmitt A., May B., Muller B., Braus D.F., and Henn F.A. Differential effects of long-term treatment with clozapine or haloperidol on GABA transporter expression. Pharmacopsychiatry 37 (2004) 171-174